Azurrx Biopharma Inc (AZRX) Stock Price & Overview
NASDAQ:AZRX
The current stock price of AZRX is 3.45 null. Today AZRX is up by 2.07%. In the past month the price decreased by -40.65%. In the past year, price decreased by -52.21%.
AZRX Key Statistics
- Market Cap
- 32.175M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.78
- Dividend Yield
- N/A
AZRX Stock Performance
AZRX Stock Chart
AZRX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to AZRX. When comparing the yearly performance of all stocks, AZRX is a bad performer in the overall market: 99.05% of all stocks are doing better.
AZRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AZRX. Both the profitability and financial health of AZRX have multiple concerns.
AZRX Earnings
AZRX Forecast & Estimates
4 analysts have analysed AZRX and the average price target is 3.4 null. This implies a price decrease of -1.45% is expected in the next year compared to the current price of 3.45.
AZRX Groups
Sector & Classification
AZRX Financial Highlights
Over the last trailing twelve months AZRX reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS decreased by -32.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -288.01% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AZRX Ownership
AZRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.33 | 402.17B | ||
| AMGN | AMGEN INC | 16.52 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.59 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.77 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.37 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.71 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.72 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 341.2 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AZRX
Company Profile
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Delray Beach, Florida and currently employs 12 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company focused on developing its pipeline of gut-restricted GI clinical drug candidates, including MS1819 and niclosamide. Its therapeutic product pipeline consists of three clinical-stage programs. The Company’s lead drug candidate is MS1819. The company is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). The company is an an oral non-systemic biologic capsule. MS1819 is in two Phase II CF clinical trials. The company is a pro-inflammatory pathway inhibitor, is a prescription small molecule drug that has been safely used on millions of patients.
Company Info
IPO: 2016-10-11
Azurrx Biopharma Inc
1615 SOUTH CONGRESS AVENUE, SUITE 103
Delray Beach FLORIDA 33445 US
CEO: James Sapirstein
Employees: 12
Phone: 16466997855.0
Azurrx Biopharma Inc / AZRX FAQ
What does AZRX do?
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Delray Beach, Florida and currently employs 12 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company focused on developing its pipeline of gut-restricted GI clinical drug candidates, including MS1819 and niclosamide. Its therapeutic product pipeline consists of three clinical-stage programs. The Company’s lead drug candidate is MS1819. The company is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). The company is an an oral non-systemic biologic capsule. MS1819 is in two Phase II CF clinical trials. The company is a pro-inflammatory pathway inhibitor, is a prescription small molecule drug that has been safely used on millions of patients.
Can you provide the latest stock price for Azurrx Biopharma Inc?
The current stock price of AZRX is 3.45 null. The price increased by 2.07% in the last trading session.
Does Azurrx Biopharma Inc pay dividends?
AZRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of AZRX stock?
AZRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is Azurrx Biopharma Inc (AZRX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AZRX.
Can you provide the market cap for Azurrx Biopharma Inc?
Azurrx Biopharma Inc (AZRX) has a market capitalization of 32.17M null. This makes AZRX a Nano Cap stock.